Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Machinatan	D C	20540	
Nashington,	D.C.	20049	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Topper James N				2. Issuer Name and Ticker or Trading Symbol NewAmsterdam Pharma Co N.V. [NAMS]							S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner								
		est) (E SCIENCES ET, SUITE 3210	Middle	÷)	Date of Earliest Transaction (Month/Day/Year) 03/26/2024 4. If Amendment, Date of Original Filed (Month/Day/Year)						Officer (give title below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					plicable			
(Street) SEATTL	E WA	A 9	98101											Form filed by More than One Reporting Person					
(City)	(Sta	ate) ((Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See In					rsuant to a o								
		Table) I - N	lon-Deriva	tive	Secur	rities	Ac	quir	ed, Di	sposed o	f, or E	Benefici	ally Own	ed				
ם		2. Transactio Date (Month/Day/Y	Execution Year) if any		ution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a 5)			Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Ordinary	Shares			03/26/202	24				P		8,429	A	\$21.5	3,008,	429	I		By Frazier Life Sciences X, L.P. ⁽¹⁾	
Ordinary	Shares													3,801,000 I			By Frazier Lifesciences Sponsor LLC ⁽²⁾		
		Та	ble I	l - Derivati (e.g., pu							posed of, convertil				d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if an	Deemed cution Date, y nth/Day/Year)		4. 5. Number of Derivative			Expiration Date (Month/Day/Year) Amount o Securities Underlyin Derivative Security (I 3 and 4)			unt of rities rlying ative rity (Instr. 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Owner Form: Direct or Indi (I) (Insi	(D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	e ercisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Steve R. Bailey, Attorney-in-Fact For James N. Topper

03/28/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} The shares are held directly by Frazier Lifesciences Sponsor LLC. The sole member of Frazier Lifesciences Sponsor LLC is Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.